Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8464872 | 0.88 | KDM4E (0.60) | KMT2AKDM4EPOLBNPC1RAB9A | |
| SCHEMBL9360758 | 0.88 | KMT2A (0.73) | KMT2AKDM4EPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL16404495 | 0.85 | KMT2A (0.69) | KMT2AKDM4EPOLBNPC1RAB9A | |
| SCHEMBL6990712 | 0.84 | KDM4E (0.72) | KMT2AKDM4EPOLBHCAR2ALDH1A1 | |
| SCHEMBL2968441 | 0.82 | KMT2A (0.66) | KMT2AKDM4EPOLBNPC1RAB9A | |
| SCHEMBL8773562 | 0.82 | KDM4E (0.57) | KMT2AKDM4EPOLBNPC1RAB9A | |
| SCHEMBL10711825 | 0.81 | RAB9A (0.70) | POLBNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3071027 | 0.81 | RAB9A (0.56) | KMT2APOLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12879817 | 0.81 | KMT2A (0.69) | KMT2AKDM4EPOLBNPC1RAB9A | |
| SCHEMBL7824993 | 0.80 | KMT2A (0.63) | KMT2AKDM4EPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | UNIV NOTTINGHAM (GB) | 2022-08-09 | — | — | US | disclosed |
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-08-06 | — | — | US | disclosed |
| EP-3684776-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | The University of Nottingham (GB) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019058132-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | CDK1, CDK11A, CDK12 | KMT2A 454/4885KDM4E 1068/4885POLB 69/4885 |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | CDK1, CDK11A, CDK12 | KMT2A 454/4885KDM4E 1068/4885POLB 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.